Management Of Glaucoma In Developing Countries: Challenges And Opportunities For Improvement

References

• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267. doi:10.1136/bjo.2005.08122416488940
   PubMed Web of Science ®Google Scholar
• Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng C-Y. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081–2090. doi:10.1016/j.ophtha.2014.05.01324974815
   PubMed Web of Science ®Google Scholar
• Varma R, Lee PP, Goldberg I, Kotak S. An assessment of the health and economic burdens of glaucoma. Am J Ophthalmol. 2011;152(4):515–522. doi:10.1016/j.ajo.2011.06.00421961848
   PubMed Web of Science ®Google Scholar
• Varma R, Ying-Lai M, Francis BA, et al. Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study. Ophthalmology. 2004;111(8):1439–1448. doi:10.1016/j.ophtha.2004.01.02515288969
   PubMed Web of Science ®Google Scholar
• Leite MT, Sakata LM, Medeiros FA. Managing glaucoma in developing countries. Arq Bras Oftalmal. 2011;74(2):83–84. doi:10.1590/S0004-27492011000200001
   PubMed Web of Science ®Google Scholar
• Chen PP. Risk and risk factors for blindness from glaucoma. Curr Opin Ophthalmol. 2004;15(2):107–111. doi:10.1097/00055735-200404000-0000915021221
   PubMedGoogle Scholar
• de Voogd S, Ikram MK, Wolfs RC, et al. Incidence of open-angle glaucoma in a general elderly population: the Rotterdam Study. Ophthalmology. 2005;112(9):1487–1493. doi:10.1016/j.ophtha.2005.04.01816039716
   PubMedGoogle Scholar
• Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991;266(3):369–374. doi:10.1001/jama.1991.034700300690262056646
   PubMed Web of Science ®Google Scholar
• Quigley HA, West SK, Rodriguez J, et al. The prevalence of glaucoma in a population-based study of Hispanic subjects: proyecto VER. Arch Ophthalmol. 2001;119(12):1819–1826. doi:10.1001/archopht.119.12.181911735794
   PubMed Web of Science ®Google Scholar
• Mitchell P, Smith W, Attebo K, Healey PR. Prevalence of open-angle glaucoma in Australia. The Blue Mountains Eye Study. Ophthalmology. 1996;103(1):1661–1669. doi:10.1016/S0161-6420(96)30449-18874440
   PubMed Web of Science ®Google Scholar
• World Health Organization. Vision 2020: The Right to Sight. Action Plan 2006–2011. Geneva: World Health Organization; 2006.
   Google Scholar
• International Finance Corporation, World Bank Group. Private Healthcare in Emerging Markets: An Investor’s Perspective. Washington, DC: World Bank Group;2015.
   Google Scholar
• Omoti AE, Osahon AI, Waziri-Erameh MJ. Pattern of presentation of primary open-angle glaucoma in Benin City, Nigeria. Trop Doct. 2006;36(2):97–100. doi:10.1258/00494750677659332316611443
   PubMed Web of Science ®Google Scholar
• Shetty P. Grey matter: aging in developing countries. Lancet. 2012;379:1285–1287. doi:10.1016/S0140-6736(12)60541-822489326
   PubMed Web of Science ®Google Scholar
• Faal H. Millennium development goals and eye health. Indian J Ophthalmol. 2012;60:411–415. doi:10.4103/0301-4738.10053822944751
   PubMedGoogle Scholar
• McKean-Cowdin R, Varma R, Wu J, Hays RD, Azen SP. Severity of visual field loss and health-related quality of life. Am J Ophthalmol. 2007;143(6):1013–1023. doi:10.1016/j.ajo.2007.02.02217399676
   PubMed Web of Science ®Google Scholar
• McKean-Cowdin R, Wang Y, Wu J, Azen SP, Varma R. Impact of visual field loss on health-related quality of life in glaucoma: the Los Angeles Latino Eye Study. Ophthalmology. 2008;115(6):941–948. doi:10.1016/j.ophtha.2007.08.03717997485
   PubMed Web of Science ®Google Scholar
• Haymes SA, Leblanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci. 2007;48(3):1149–1155. doi:10.1167/iovs.06-088617325158
   PubMedGoogle Scholar
• Rein DB, Zhang P, Wirth KE, et al. The economic burden of major adult visual disorders in the United States. Arch Ophthalmol. 2006;124(12):1754–1760. doi:10.1001/archopht.124.12.175417159036
   PubMedGoogle Scholar
• Taylor HR, Pezzullo ML, Keeffe JE. The economic impact and cost of visual impairment in Australia. Br J Ophthalmol. 2006;90(3):272–275. doi:10.1136/bjo.2005.08098616488942
   PubMedGoogle Scholar
• Lazcano-Gomez G, Ramos-Cadena M, Torres-Tamayo M, et al. Cost of glaucoma treatment in a developing country over a 5-year period. Medicine. 2016;95(47):1–5. doi:10.1097/MD.0000000000005341
   Web of Science ®Google Scholar
• Adio AO, Onua AA. Economic burden of glaucoma in Rivers State, Nigeria. Clin Ophthalmol. 2012;6:2023–2031. doi:10.2147/OPTH.S3714523271881
   PubMedGoogle Scholar
• Poulsen PB, Buchholz P, Walt JG, Christensen TL, Thygesen J. Cost-analysis of glaucoma-related blindness in Europe. Int Congress Ser. 2005;1282:262–266. doi:10.1016/j.ics.2005.05.091
   Google Scholar
• Thygesen J, Aagren M, Arnavielle S, et al. Late-stage, primary open-angle glaucoma in Europe: social and health care maintenance costs and quality of life of patients from 4 countries. Curr Med Res Opin. 2008;24(6):1763–1770. doi:10.1185/0300799080211106818559164
   PubMed Web of Science ®Google Scholar
• Mabuchi F, Yoshimura K, Kashiwagi K, et al. High prevalence of anxiety and depression in patients with primary open-angle glaucoma. J Glaucoma. 2008;17(7):552–557. doi:10.1097/IJG.0b013e31816299d418854732
   PubMed Web of Science ®Google Scholar
• Zhang X, Olson DJ, Le P, Lin F-C, Fleischman D, Davis RM. The association between glaucoma, anxiety, and depression in a large population. Am J Ophthalmol. 2017;183:37–41. doi:10.1016/j.ajo.2017.07.02128760639
   PubMed Web of Science ®Google Scholar
• Caceres V. Managing fear and depression in glaucoma patients. American Society of Cataract and Refractive SurgeryEyeWorld. 2012. Available from: https://www.eyeworld.org/article-managing-fear-and-depression. Accessed 116, 2018.
   Google Scholar
• Moore D, West J. Glaucoma in the developing world. American Academy of Ophthalmology EyeWiki; 2019. Available from: http://eyewiki.aao.org/Glaucoma_in_the_Developing_World. Accessed July 20, 2019.
   Google Scholar
• Gupta V, Srinivasan G, Mei SS, et al. Utility values among glaucoma patients: an impact on the quality of life. Br J Ophthalmol. 2005;89:1241–1244. doi:10.1136/bjo.2005.06885816170108
   PubMed Web of Science ®Google Scholar
• Palleta Guedes RA, Palleta Guedes VM, Freitas SM, et al. Utility values for glaucoma in Brazil and their correlation with visual function. Clin Ophthalmol. 2014;8:529–535. doi:10.2147/OPTH.S6010524648717
   PubMedGoogle Scholar
• Adekoya BJ, Adepoju FG, Moshood KF, et al. Challenges in the management of glaucoma in a developing country; a qualitative study of providers’ perspectives. Niger J Med. 2015;24:315–322.27487608
   PubMedGoogle Scholar
• Thomas R. Glaucoma in developing countries. Indian J Ophthalmol. 2012;60:446–450. doi:10.4103/0301-4738.10054622944757
   PubMedGoogle Scholar
• Rotshtein A, Karkabi K, Geyer O, et al. Primary care physicians’ role perception and self-reported performance in glaucoma care: a survey study. BMC Res Notes. 2015;8:776. doi:10.1186/s13104-015-1770-z26653898
   PubMedGoogle Scholar
• Du Toit R, Faal HB, Etya’ale D, et al. Evidence for integrating eye health into primary health care in Africa: a health systems strengthening approach. BMC Health Serv Res. 2013;13:102. doi:10.1186/1472-6963-13-10223506686
   PubMed Web of Science ®Google Scholar
• Rao GN. The Barrie Jones Lecture—eye care for the neglected population: challenges and solutions. Eye (Lond). 2015;29:30–45. doi:10.1038/eye.2014.23925567375
   PubMed Web of Science ®Google Scholar
• Yan X, Liu T, Gruber L, et al. Attitudes of physicians, patients, and village health workers toward glaucoma and diabetic retinopathy in rural China: a focus group study. Arch Ophthalmol. 2012;130:761–770. doi:10.1001/archophthalmol.2012.14522801838
   PubMedGoogle Scholar
• Onabolu OO, Bodunde OT. Awareness and knowledge of glaucoma among primary care givers in a developing country. Ann Trop Med Public Health. 2014;7:5–8. doi:10.4103/1755-6783.144997
   Google Scholar
• Mohammadpour M, Heidari Z, Mirghorbani M, et al. Smartphones, tele-ophthalmology, and VISION 2020. Int J Ophthalmol. 2017;10:1909–1918.29259912
   PubMed Web of Science ®Google Scholar
• Ooms A, Khoury AS, Szirth B. Teleglaucoma. Am Acad Ophthalmol. 2018 Available from: http://eyewiki.aao.org/Tele-Glaucoma. Accessed August 4, 2019.
   Google Scholar
• Rani PK, Nangia V, Murthy KR, Khanna RC, Das T. Community care for diabetic retinopathy and glaucoma in India: a panel discussion. Indian J Ophthalmol. 2018;66(7):916–920. doi:10.4103/ijo.IJO_910_1729941730
   PubMedGoogle Scholar
• Thomas SM, Jeyaraman MM, Hodge WG, et al. The effectiveness of teleglaucoma versus in-patient examination for glaucoma screening: a systematic review and meta-analysis. PLoS One. 2014;9:e113779. doi:10.1371/journal.pone.011377925479593
   PubMedGoogle Scholar
• Kappal R, Mehndiratta A, Anandaraj P, et al. Current impact, future prospects and implications of mobile healthcare in India. Cent Asian J Glob Health. 2014;3:116.29755887
   PubMedGoogle Scholar
• Damji KF. Strengthening institutional capacity for glaucoma care in sub-Saharan Africa. Middle East Afr J Ophthalmol. 2013;20:107–110. doi:10.4103/0974-9233.11060123741129
   PubMedGoogle Scholar
• Ramchandani M. Glaucoma in the developing world. Comment on: effect of beta radiation on success of glaucoma drainage surgery in South Africa: randomised controlled trial. [BMJ. 2006]. BMJ. 2006;333:932. doi:10.1136/bmj.39016.626771.8017082526
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–355. doi:10.1097/IJG.0b013e31815c5f4f18703943
   PubMed Web of Science ®Google Scholar
• Schein OD, Munuz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124(6):723–728. doi:10.1016/S0002-9394(14)71688-59402817
   PubMed Web of Science ®Google Scholar
• Costa VP, Marcon IM, Galvão Filho RP, Malta RFS. The prevalence of ocular surface complaints in Brazilian paients with glaucoma or ocular hypertension. Arq Bras Oftalmol. 2013;76(4):221–225. doi:10.1590/S0004-2749201300040000624061832
   PubMedGoogle Scholar
• Ruangvaravate N, Prabhasawat P, Vachirasakchai V, Tantimala R. High prevalence of ocular surface disease among glaucoma patients in Thailand. J Ocul Pharmacol Ther. 2018;34(5):387–394. doi:10.1089/jop.2017.010429596033
   PubMedGoogle Scholar
• Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefes Arch Clin Exp Ophthalmol. 2008;246:1593–1601. doi:10.1007/s00417-008-0881-918648841
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, Stewart JA, Stewart WC, Jasek MC. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29(6):618–621. doi:10.1097/ICO.0b013e3181c325b220386433
   PubMed Web of Science ®Google Scholar
• Terai N, Muller-Holz M, Spoerl E, et al. Short term effect of topical antiglaucoma medication on tear-film stability, tear secretion, and corneal sensitivity in healthy subjects. Clin Ophthalmol. 2011;5(1):517–525. doi:10.2147/OPTH.S1884921573041
   PubMedGoogle Scholar
• Stewart WC, Stewart JA, Nelson LA. Ocular surface disease in patients with ocular hypertension and glaucoma. Curr Eye Res. 2011;36(5):391–398. doi:10.3109/02713683.2011.56234021501071
   PubMed Web of Science ®Google Scholar
• Gomes JAP, Azar DT, Baudouin C, et al. TFOS DEWS II iatrogenic report. Ocul Surf. 2017;15:511–538. doi:10.1016/j.jtos.2017.05.00428736341
   PubMed Web of Science ®Google Scholar
• Torricelli AA, Matsuda M, Novaes P, et al. Effects of ambient levels of traffic-derived air pollution on the ocular surface: analysis of symptoms, conjunctival goblet cell count and mucin 5AC gene expression. Environ Res. 2014;131:59–63. doi:10.1016/j.envres.2014.02.01424657517
   PubMed Web of Science ®Google Scholar
• Torricelli AA, Novaes P, Matsuda M, et al. Correlation between signs and symptoms of ocular surface dysfunction and tear osmolarity with ambient levels of air pollution in a large metropolitan area. Cornea. 2013;32(4):e11–5. doi:10.1097/ICO.0b013e31825e845d22968361
   PubMed Web of Science ®Google Scholar
• Torricelli AA, Novaes P, Matsuda M, et al. Ocular surface adverse effects of ambient levels of air pollution. Arq Bras Oftalmol. 2011;74(5):377–381. Review. doi:10.1590/S0004-2749201100050001622184003
   PubMedGoogle Scholar
• Saxena R, Srivastava S, Trivedi D, et al. Impact of environmental pollution on the eye. Acta Ophthalmol Scand. 2003;81:491–494. doi:10.1034/j.1600-0420.2003.00119.x14510797
   PubMedGoogle Scholar
• Kastelan S, Tomic M, Soldo KM, et al. How ocular surface disease impacts the glaucoma treatment outcome. Biomed Res Intl. 2013;2013:1–7. doi:10.1155/2013/696328
   Web of Science ®Google Scholar
• Uchino M, Shaumberg DA. Dry eye disease: impact on quality of life and vision. Curr Ophthalmol Rep. 2014;1(2):51–57. doi:10.1007/s40135-013-0009-1
   Google Scholar
• Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86:418–423. doi:10.1136/bjo.86.4.41811914211
   PubMed Web of Science ®Google Scholar
• Feroze KB, Khazaeni L. Steroid Induced Glaucoma. StatPearls Publishing LLC; 2019.
   Google Scholar
• Batra R, Tailor R, Mohamed S. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J Glaucoma. 2014;23:56–60. doi:10.1097/IJG.0b013e318264cd6822828007
   PubMed Web of Science ®Google Scholar
• Kahook MY. Branded vs. generic: proceed with caution. Rev Ophthalmol. 2014 Available from: https://www.reviewofophthalmology.com/article/branded-vs-generic-proceed-with-caution. Accessed January 16, 2018.
   Google Scholar
• Terrie YC. Ophthalmic medications: the safety and efficacy of brand-name versus generic formulations. US Pharm. 2015;40(suppl):56–66.
   Google Scholar
• Zore M, Harris A, Tobe LA, et al. Generic medications in ophthalmology. Br J Ophthalmol. 2013;97:253–257. doi:10.1136/bjophthalmol-2012-30224523143788
   PubMedGoogle Scholar
• Karmel M. Generic vs. branded drugs: just how equal is equal? Am Acad Ophthalmol EyeNet. 2011 Available from: https://www.aao.org/eyenet/article/generic-vs-branded-drugs-just-how-equal-is-equal. Accessed January 16, 2018.
   Google Scholar
• Banga HK, Gupta AK, Singh G. Volumetric and cost evaluation study of glaucoma medical therapy. Int J Appl Basic Med Res. 2015;5:96–99. doi:10.4103/2229-516X.15715326097815
   PubMedGoogle Scholar
• European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. European Glaucoma Society; 2014 Available from: http://www.eugs.org/eng/EGS_guidelines4.asp. Accessed January 16, 2018.
   Google Scholar
• Holló G, Katsanos A, Boboridis KG, et al. Preservative-free prostaglandin analogs and prostaglandin/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs. 2018;78:39–64. doi:10.1007/s40265-017-0843-929196953
   PubMed Web of Science ®Google Scholar
• Fiscella R, Green A, Patuszynski DH, et al. Medical therapy cost considerations for glaucoma. Am J Ophthalmol. 2003;136:18–25. doi:10.1016/S0002-9394(03)00102-812834665
   PubMed Web of Science ®Google Scholar
• Shedden A, Adamsons IA, Getson AJ, et al. Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPT™) in patients with elevated intraocular pressure in a randomized clinical trial. Graefes Arch Clin Exp Ophthalmol. 2010;248:1757–1764. doi:10.1007/s00417-010-1397-720437244
   PubMed Web of Science ®Google Scholar
• Boyle JE, Ghosh K, Gieser DK, et al. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Dorzolamide-Timolol Study Group. Ophthalmology. 1998;105(10):1945–1951. doi:10.1016/S0161-6420(98)91046-69787368
   PubMed Web of Science ®Google Scholar
• Strohmaier K, Snyder E, DuBiner H, et al. The efficacy and safety of the dorzolamide-timolol combination versus the combination administration of its components. Ophthalmology. 1998;105:1936–1944. doi:10.1016/S0161-6420(98)91045-49787367
   PubMed Web of Science ®Google Scholar
• Clineschmidt CM, Williams RD, Snyder E, et al. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 1998;105:1952–1959. doi:10.1016/S0161-6420(98)91047-89787369
   PubMed Web of Science ®Google Scholar
• Parmaksiz S, Yüksel N, Karabas VL, et al. A comparison of travoprost, latanoprost, and the fixed combination of dorzolamide and timolol in patients with pseudoexfoliation glaucoma. Eur J Ophthalmol. 2006;16(1):73–80. doi:10.1177/112067210601600113
   Web of Science ®Google Scholar
• He M, Wang W, Huang W. Efficacy and tolerability of the fixed combinations latanoprost/timolol versus dorzolamide/timolol in patients with elevated intraocular pressure: a meta-analysis of randomized controlled trials. PLoS One. 2013;8(12):e83606. doi:10.1371/journal.pone.008360624349536
   PubMed Web of Science ®Google Scholar
• Babić N, Veljko A, Miljković A, et al. Comparison of the efficacy and safety of fixed combination travoprost/timolol and dorzolamide/timolol in patients with primary open-angle glaucoma and ocular hypertension. Srp Arh Celok Lek. 2013;141(7–8):441–446. doi:10.2298/SARH1308441B24073548
   PubMedGoogle Scholar
• Sezgin Akçay BI, Güney E, Bozkurt KT, Ünlü C, Akçali G. The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2013;29:882–886. doi:10.1089/jop.2013.010224180628
   PubMed Web of Science ®Google Scholar
• Konstas AG, Quaranta L, Yan DB, et al. Twenty-four hour efficacy with the dorzolamide/timolol-fixed combination compared with the brimonidine/timolol fixed combination in primary open-angle glaucoma. Eye (Lond). 2012;26(1):80–87. doi:10.1038/eye.2011.23921960068
   PubMedGoogle Scholar
• Lesk MR, Koulis T, Sampalis F, et al. Effectiveness and safety of dorzolamide–timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother. 2008;42:498–504. doi:10.1345/aph.1K56518364402
   PubMed Web of Science ®Google Scholar
• Quaranta L, Miglior S, Floriani I, et al. Effects of the timolol-dorzolamide fixed combination and latanoprost on circadian diastolic ocular perfusion pressure in glaucoma. Invest Ophthalmol Vis Sci. 2008;49:4226–4231. doi:10.1167/iovs.08-174418502991
   PubMed Web of Science ®Google Scholar
• Takeda S, Mimura T, Matsubara M. Effect of 3 years of treatment with a dorzolamide/timolol (1%/0.5%) combination on intraocular pressure. Clin Ophthalmol. 2014;8:1773–1782.25228795
   PubMedGoogle Scholar
• Hutzelmann J, Owens S, Shedden A, et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. International Clinical Equivalence Study Group. Br J Ophthalmol. 1998;82(11):1249–1253. doi:10.1136/bjo.82.11.12499924327
   PubMed Web of Science ®Google Scholar
• Galose MS, Elsaied HM, Macky TA, et al. Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: a hospital-based, prospective, randomized study. Indian J Ophthalmol. 2016;64(2):127–131. doi:10.4103/0301-4738.17971827050347
   PubMed Web of Science ®Google Scholar
• Lee NY, Park HY, Park CK. Comparison of the effects of dorzolamide/timolol fixed combination versus latanoprost on intraocular pressure and ocular perfusion pressure in patients with normal-tension glaucoma: a randomized, crossover clinical trial. PLoS One. 2016;12(11):1–16.
   Google Scholar
• Inoue K, Shiokawa M, Sugahara M, et al. Three-month evaluation of dorzolamide hydrochloride/timolol maleate fixed-combination eye drops versus the separate use of both drugs. Jpn J Ophthalmol. 2012;56(6):559–563. doi:10.1007/s10384-012-0186-823001284
   PubMedGoogle Scholar
• Crichton AC, Harasymowycz P, Hutnik CM, et al. Effectiveness of dorzolamide–timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: the COSOPT first-line study. J Ocul Pharmacol Ther. 2010;26(5):503–511. doi:10.1089/jop.2010.003220874498
   PubMed Web of Science ®Google Scholar
• Uusitalo H, Pillunat LE, Ropo A, et al. Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study. Acta Ophthalmol. 2010;88(1):12–19. doi:10.1111/j.1755-3768.2010.01862.x20420586
   PubMed Web of Science ®Google Scholar
• Hamacher T, Airaksinen J, Saarela V, Liinamaa MJ, Richter U, Ropo A. Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis. Acta Ophthalmol. 2008;Suppl (Oxf) 242:14–19. doi:10.1111/j.1755-3768.2008.01381.x
   Web of Science ®Google Scholar
• Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmol. 2010;88:329–336. doi:10.1111/j.1755-3768.2010.01907.x20546237
   PubMed Web of Science ®Google Scholar
• Lanzl I, Hamacher T, Rosbach K, et al. Preservative-free tafluprost in the treatment of naive patients with glaucoma and ocular hypertension. Clin Ophthalmol. 2013;7:901–910.23717036
   PubMedGoogle Scholar
• Egorov E, Ropo A. Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma. Eur J Ophthalmol. 2009;19(2):214–222. doi:10.1177/11206721090190020719253237
   PubMedGoogle Scholar
• Hommer A, Kimmich F. Switching patients from preserved prostaglandin analog monotherapy to preservative-free tafluprost. Clin Ophthalmol. 2011;5:623–631.21629567
   PubMedGoogle Scholar
• Konstas AGP, Quaranta L, Katsanos A, et al. Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. Br J Ophthalmol. 2013;97:1–6.23077226
   PubMed Web of Science ®Google Scholar
• Mochizuki H, Itakura H, Yokoyama T, Takamatsu M, Kiuchi Y. Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects. Jpn J Ophthalmol. 2010;54:286–290. doi:10.1007/s10384-010-0828-720700794
   PubMedGoogle Scholar
• Uusitalo H, Egorov E, Kaarniranta K, Astakhov Y, Ropo A. on behalf of the Switch Study Tafluprost Study Groups. Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials. Clin Ophthalmol. 2016;10:445–454. doi:10.2147/OPTH27041987
   PubMed Web of Science ®Google Scholar
• Hommer A, Mohammed Ramez O, Burchert M, Kimmich F. IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma. Curr Med Res Opin. 2010;26(8):1905–1913. doi:10.1185/03007995.2010.49203020553122
   PubMed Web of Science ®Google Scholar
• Erb C, Lanzl I, Seidova SF, Kimmich F. Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension. Adv Ther. 2011;28(7):575–585. doi:10.1007/s12325-011-0038-921725844
   PubMedGoogle Scholar
• Makino K, Charles H, Tilden D, et al. Health economic evaluation of preservative-free tafluprost versus preserved latanoprost in the treatment of open-angle glaucoma or ocular hypertension (OH). Value Health. 2010;15:A643. doi:10.1016/j.jval.2012.08.242
   Web of Science ®Google Scholar
• Payet S, Denis P, Berdeaux G, Launois R. Assessment of the cost effectiveness of travoprost versus latanoprost as single agents for treatment of glaucoma in France. Clin Drug Investig. 2008;28(3):183–198. doi:10.2165/00044011-200828030-00005
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Guideline on Health Policy and System Support to Optimize Community Health Worker Programmes. World Health Organization; 2018 Available from: https://apps.who.int/iris/bitstream/handle/10665/275474/9789241550369-eng.pdf. Accessed August 4, 2019.
   Google Scholar